Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
OncoCyte hosting KOL webinar on DetermaIO » 08:19
06/22/22
06/22
08:19
06/22/22
08:19
OCX

OncoCyte

/

+

Oncocyte Corporation…

Oncocyte Corporation announced that it will host a key opinion leader webinar on the role of DetermalO and the tumor microenvironment in clinical practice on Tuesday, June 28, 2022, at 10:00am Eastern Time. The webinar will feature presentations from KOLs Chiara Cremolini, MD, PhD, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy, and Adam Brufsky, MD, PhD, University of Pittsburgh School of Medicine. Dr. Cremolini will provide an expert data overview on the ASCO 2022 poster session: An immune-related gene expression profile to predict the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: a translational analysis of the phase II randomized AtezoTRIBE study. Subsequently, Dr. Brufsky and Dr.Cremolini will take part in an expert fireside chat on assessing the tumor micro-environment to identify potential responders to immunotherapy in Colon and Breast Cancer, and review how this could impact clinical practice and management of patients.

ShowHide Related Items >><<
OCX OncoCyte
/

+

OCX OncoCyte
/

+

05/24/22 Stephens
Stephens downgrades OncoCyte to Equal Weight on limited near-term upside
05/24/22 Stephens
OncoCyte downgraded to Equal Weight from Overweight at Stephens
05/15/22 Piper Sandler
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler
03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
OCX OncoCyte
/

+

  • 14
    Apr
OCX OncoCyte
/

+

Over a month ago
Hot Stocks
OncoCyte presents DetermaIO data at ASCO supporting immunotherapy expansion » 17:14
05/26/22
05/26
17:14
05/26/22
17:14
OCX

OncoCyte

$1.02 /

+0.0349 (+3.56%)

Oncocyte "announced…

Oncocyte "announced new data from ongoing clinical research evaluating the utility of DetermaIO, the Company's proprietary test designed to determine the likelihood of benefit of immune checkpoint inhibitors, at the upcoming American Society of Clinical Oncology Annual Meeting, ASCO, taking place June 3-7, 2022 virtually and in-person in Chicago. DetermaIO was launched via an Early Access Program in Q4 of 2021 and is the first and only commercial test to assess multiple components of the tumor immune microenvironment, giving insight into the biology of the tumor that allows for physicians and their patients to make informed decisions about their treatment journey. The three posters to be presented by Oncocyte add to the growing body of evidence showing that the test identifies patients who respond to ICIs - including Keytruda, Opdivo, Tecentriq and Imfinzi - in lung, bladder, kidney, triple-negative breast, and now colon and gastric cancers, suggesting a pan-cancer utility for the test in both primary and metastatic settings."

ShowHide Related Items >><<
OCX OncoCyte
$1.02 /

+0.0349 (+3.56%)

OCX OncoCyte
$1.02 /

+0.0349 (+3.56%)

05/24/22 Stephens
Stephens downgrades OncoCyte to Equal Weight on limited near-term upside
05/24/22 Stephens
OncoCyte downgraded to Equal Weight from Overweight at Stephens
05/15/22 Piper Sandler
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler
03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
OCX OncoCyte
$1.02 /

+0.0349 (+3.56%)

  • 14
    Apr
OCX OncoCyte
$1.02 /

+0.0349 (+3.56%)

Downgrade
Stephens downgrades OncoCyte to Equal Weight on limited near-term upside » 11:00
05/24/22
05/24
11:00
05/24/22
11:00
OCX

OncoCyte

$1.02 /

-0.05 (-4.67%)

As reported before the…

As reported before the open, Stephens analyst Mason Carrico downgraded OncoCyte to Equal Weight from Overweight with a price target of $1.25, down from $2. While he continues to see long-term value in OncoCyte's portfolio, he sees relatively limited near-term upside with timelines having been pushed out in recent quarters, Carrico told investors. Though he expects a strong ramp in TheraSure test volumes, relatively minimal reimbursement and a small commercial team could result in lower than anticipated revenue in FY23 while DetermaIO likely won't begin contributing revenue until 2024, Carrico said.

ShowHide Related Items >><<
OCX OncoCyte
$1.02 /

-0.05 (-4.67%)

OCX OncoCyte
$1.02 /

-0.05 (-4.67%)

05/24/22 Stephens
OncoCyte downgraded to Equal Weight from Overweight at Stephens
05/15/22 Piper Sandler
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler
03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
OCX OncoCyte
$1.02 /

-0.05 (-4.67%)

  • 14
    Apr
OCX OncoCyte
$1.02 /

-0.05 (-4.67%)

Downgrade
OncoCyte downgraded to Equal Weight from Overweight at Stephens » 07:54
05/24/22
05/24
07:54
05/24/22
07:54
OCX

OncoCyte

$1.07 /

-0.04 (-3.60%)

Stephens analyst Mason…

Stephens analyst Mason Carrico downgraded OncoCyte to Equal Weight from Overweight.

ShowHide Related Items >><<
OCX OncoCyte
$1.07 /

-0.04 (-3.60%)

OCX OncoCyte
$1.07 /

-0.04 (-3.60%)

05/15/22 Piper Sandler
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler
03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
OCX OncoCyte
$1.07 /

-0.04 (-3.60%)

  • 14
    Apr
OCX OncoCyte
$1.07 /

-0.04 (-3.60%)

Recommendations
OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler » 21:15
05/15/22
05/15
21:15
05/15/22
21:15
OCX

OncoCyte

$1.12 /

+0.025 (+2.28%)

Piper Sandler analyst…

Piper Sandler analyst David Westenberg lowered the firm's price target on OncoCyte to $1.40 from $1.80 and keeps an Overweight rating on the shares post the earnings release. The analyst dropped price targets in the life science tools and genomics space to reflect movements in comp valuations.

ShowHide Related Items >><<
OCX OncoCyte
$1.12 /

+0.025 (+2.28%)

OCX OncoCyte
$1.12 /

+0.025 (+2.28%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
OCX OncoCyte
$1.12 /

+0.025 (+2.28%)

  • 14
    Apr
OCX OncoCyte
$1.12 /

+0.025 (+2.28%)

Earnings
OncoCyte reports Q1 EPS (11c), consensus (12c) » 16:16
05/11/22
05/11
16:16
05/11/22
16:16
OCX

OncoCyte

$1.13 /

-0.025 (-2.17%)

Reports Q1 revenue $1.4M,…

Reports Q1 revenue $1.4M, consensus $2.24M. "We continued to make solid progress in the first quarter, delivering 73% year over year growth in DetermaRx sample volumes and successfully onboarding new physicians and accounts. We also successfully completed an underwritten financing to strengthen our balance sheet and fuel our upcoming product launch efforts," said Ron Andrews, President and Chief Executive Officer of Oncocyte. "Looking ahead, we remain enthusiastic about our upcoming DetermaIO data releases at ASCO in early June and the continued rapid progress we have made to launch our transplant business as we announced last week. We also remain on track to submit three additional oncology tests, DetermaIO, DetermaTx and DetermaCNI, for reimbursement over the next 12-18 months. I appreciate the continued support of our shareholders and look forward to updating you as we execute on our strategic plans."

ShowHide Related Items >><<
OCX OncoCyte
$1.13 /

-0.025 (-2.17%)

OCX OncoCyte
$1.13 /

-0.025 (-2.17%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
OCX OncoCyte
$1.13 /

-0.025 (-2.17%)

  • 14
    Apr
OCX OncoCyte
$1.13 /

-0.025 (-2.17%)

Hot Stocks
OncoCyte completes validation of TheraSure Transplant Monitoring test » 08:39
05/05/22
05/05
08:39
05/05/22
08:39
OCX

OncoCyte

$1.21 /

+0.05 (+4.31%)

Oncocyte announced that…

Oncocyte announced that it has completed development of its proprietary TheraSure Transplant Monitoring test for liver transplant patients. This announcement marks the successful completion of technology transfer and Oncocyte's readiness to deploy TheraSure following the Company's acquisition of Chronix Biomedical. "Today's announcement marks the first product to be launched clinically from our Chronix acquisition completed in April 2021. The tech transfer of the proprietary blood based technology used to develop TheraSure was an important undertaking for our R&D team in Germany and our CLIA lab team in Nashville, and I am extremely proud of the herculean effort put forth to meet the aggressive timeline we set last year to put us in a position to launch the liver indication in the first half of 2022," said Ron Andrews, President and CEO of Oncocyte. "Management believes that the streamlined workflow developed by our two expert PCR development teams paves the way for expedited validation of TheraSure for kidney and heart transplants and prepares the Company for the important work ahead to convert the lab workflow into a kit."

ShowHide Related Items >><<
OCX OncoCyte
$1.21 /

+0.05 (+4.31%)

OCX OncoCyte
$1.21 /

+0.05 (+4.31%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
OCX OncoCyte
$1.21 /

+0.05 (+4.31%)

  • 14
    Apr
OCX OncoCyte
$1.21 /

+0.05 (+4.31%)

On The Fly
Fly Insider: Sonic Automotive, Moderna among week's notable insider trades » 15:40
04/18/22
04/18
15:40
04/18/22
15:40
CMPO

CompoSecure

$7.70 /

+0.52 (+7.24%)

, PRTY

Party City

$3.63 /

-0.2 (-5.23%)

, SAH

Sonic Automotive

$43.85 /

+0.53 (+1.22%)

, OCX

OncoCyte

$1.21 /

-0.05 (-3.97%)

, CERE

Cerevel Therapeutics

$31.90 /

-0.59 (-1.82%)

, ETSY

Etsy

$109.01 /

-6.68 (-5.77%)

, HUBS

HubSpot

$428.53 /

-17.72 (-3.97%)

, MRNA

Moderna

$156.20 /

-9.43 (-5.69%)

Welcome to "Fly Insider,"…

ShowHide Related Items >><<
SAH Sonic Automotive
$43.85 /

+0.53 (+1.22%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

CERE Cerevel Therapeutics
$31.90 /

-0.59 (-1.82%)

CMPO CompoSecure
$7.70 /

+0.52 (+7.24%)

01/28/22 Needham
CompoSecure initiated with a Buy at Needham
01/07/22 B. Riley
CompoSecure initiated with a Buy at B. Riley
PRTY Party City
$3.63 /

-0.2 (-5.23%)

SAH Sonic Automotive
$43.85 /

+0.53 (+1.22%)

04/07/22 JPMorgan
Sonic Automotive downgraded to Neutral from Overweight at JPMorgan
11/17/21 Morgan Stanley
Penske Automotive downgraded to Underweight at Morgan Stanley
11/17/21 Morgan Stanley
Sonic Automotive downgraded to Underweight at Morgan Stanley
11/17/21 Morgan Stanley
Sonic Automotive downgraded to Underweight from Equal Weight at Morgan Stanley
OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
CERE Cerevel Therapeutics
$31.90 /

-0.59 (-1.82%)

02/14/22 Goldman Sachs
Cerevel Therapeutics initiated with a Neutral at Goldman Sachs
01/05/22 JPMorgan
Cerevel Therapeutics initiated with an Overweight at JPMorgan
12/16/21 H.C. Wainwright
Cerevel Therapeutics initiated with a Buy at H.C. Wainwright
11/10/21 Stifel
Cerevel Therapeutics price target raised to $50 from $33 at Stifel
ETSY Etsy
$109.01 /

-6.68 (-5.77%)

04/13/22 Oppenheimer
Etsy price target lowered to $175 from $215 at Oppenheimer
03/31/22 Stifel
Poshmark downgraded to Hold from Buy at Stifel
03/29/22 Loop Capital
Etsy downgraded to Hold from Buy at Loop Capital
03/29/22 Loop Capital
Etsy downgraded to Hold from Buy at Loop Capital
HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

03/21/22 Stifel
HubSpot price target lowered to $700 from $850 at Stifel
03/15/22 Wells Fargo
HubSpot price target lowered to $675 from $725 at Wells Fargo
02/14/22 Canaccord
HubSpot price target lowered to $675 from $845 at Canaccord
02/11/22 Truist
HubSpot price target lowered to $700 from $900 at Truist
MRNA Moderna
$156.20 /

-9.43 (-5.69%)

04/11/22 Piper Sandler
CFO leaves Dentsply for Moderna, outside replacement more likely, says Piper
03/25/22 Piper Sandler
Moderna pipeline growing and 'de-risked,' says Piper Sandler
03/23/22 Piper Sandler
Moderna's Phase II/III KidCOVE trial meets endpoints, says Piper Sandler
03/10/22 Piper Sandler
Moderna's Vaccine Day to highlight expanding pipeline, says Piper Sandler
SAH Sonic Automotive
$43.85 /

+0.53 (+1.22%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

CMPO CompoSecure
$7.70 /

+0.52 (+7.24%)

CERE Cerevel Therapeutics
$31.90 /

-0.59 (-1.82%)

  • 14
    Apr
  • 02
    Jul
MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

OCX OncoCyte
$1.21 /

-0.05 (-3.97%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

HUBS HubSpot
$428.53 /

-17.72 (-3.97%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

CMPO CompoSecure
$7.70 /

+0.52 (+7.24%)

PRTY Party City
$3.63 /

-0.2 (-5.23%)

MRNA Moderna
$156.20 /

-9.43 (-5.69%)

ETSY Etsy
$109.01 /

-6.68 (-5.77%)

Syndicate
OncoCyte 26.27M share Spot Secondary priced at $1.33 » 06:25
04/14/22
04/14
06:25
04/14/22
06:25
OCX

OncoCyte

$1.26 /

-0.02 (-1.56%)

OncoCyte announced today…

OncoCyte announced today the pricing of an underwritten public offering of 26,266,417 shares of its common stock, together with warrants to purchase up to an aggregate of 13,133,208.5 shares of its common stock. Each share of common stock is being sold together with one warrant to purchase 0.5 shares of common stock at a combined offering price of $1.3325 for total gross proceeds of approximately $35 million, before underwriting discounts and commissions and offering expenses payable by Oncocyte. The warrants have an exercise price of $1.53 per share, are exercisable immediately, and will expire five years following the date of issuance. The offering is expected to close on or about April 19, 2022, subject to the satisfaction or waiver of customary closing conditions. BTIG and Needham are acting as joint book running managers for the offering.

ShowHide Related Items >><<
OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

  • 14
    Apr
OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

On The Fly
Fly Intel: After-Hours Movers » 17:50
04/13/22
04/13
17:50
04/13/22
17:50
VLNS

Valens

$1.30 /

+0.08 (+6.56%)

, AGX

Argan

$39.55 /

-0.15 (-0.38%)

, AIRG

Airgain

$6.98 /

+0.065 (+0.94%)

, ANSS

Ansys

$295.81 /

+4.49 (+1.54%)

, DLO

dLocal

$27.55 /

+0.725 (+2.70%)

, DOW

Dow Inc.

$64.19 /

+0.895 (+1.41%)

, CMBM

Cambium Networks

$20.29 /

+0.16 (+0.79%)

, RENT

Rent The Runway

$5.72 /

+0.37 (+6.92%)

, PTGX

Protagonist Therapeutics

$25.52 /

+1.955 (+8.30%)

, OCX

OncoCyte

$1.26 /

-0.02 (-1.56%)

, ES

Eversource

$92.52 /

-0.41 (-0.44%)

Check out this evening's…

ShowHide Related Items >><<
VLNS Valens
$1.30 /

+0.08 (+6.56%)

RENT Rent The Runway
$5.72 /

+0.37 (+6.92%)

PTGX Protagonist Therapeutics
$25.52 /

+1.955 (+8.30%)

OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

ES Eversource
$92.52 /

-0.41 (-0.44%)

DOW Dow Inc.
$64.19 /

+0.895 (+1.41%)

DLO dLocal
$27.55 /

+0.725 (+2.70%)

CMBM Cambium Networks
$20.29 /

+0.16 (+0.79%)

ANSS Ansys
$295.81 /

+4.49 (+1.54%)

AIRG Airgain
$6.98 /

+0.065 (+0.94%)

AGX Argan
$39.55 /

-0.15 (-0.38%)

VLNS Valens
$1.30 /

+0.08 (+6.56%)

03/02/22 Raymond James
Valens downgraded to Underperform from Market Perform at Raymond James
03/02/22 Canaccord
Valens price target lowered to C$7 from C$9 at Canaccord
02/14/22 Raymond James
Valens price target lowered to C$5 from C$7.50 at Raymond James
02/09/22 Desjardins
Valens price target lowered to C$3.25 from C$3.50 at Desjardins
AGX Argan
$39.55 /

-0.15 (-0.38%)

AIRG Airgain
$6.98 /

+0.065 (+0.94%)

02/25/22 Cowen
Airgain price target lowered to $11 from $13 at Cowen
02/22/22 B. Riley
B. Riley downgrades Airgain, halves price target into results
02/22/22 B. Riley
Airgain downgraded to Neutral from Buy at B. Riley
12/16/21 Craig-Hallum
Airgain initiated with a Buy at Craig-Hallum
ANSS Ansys
$295.81 /

+4.49 (+1.54%)

03/31/22 Jefferies
Jefferies says Altair, Bentley Systems among 'logical' targets for Siemens
03/28/22 Mizuho
Ansys initiated with a Neutral at Mizuho
03/25/22 Daiwa
Ansys initiated with a Sell at Daiwa
02/25/22 Barclays
Ansys price target lowered to $260 from $305 at Barclays
DLO dLocal
$27.55 /

+0.725 (+2.70%)

04/13/22 Piper Sandler
dLocal initiated with an Overweight at Piper Sandler
02/10/22 UBS
dLocal upgraded to Buy at UBS on 'attractive valuation'
02/10/22 UBS
dLocal upgraded to Buy from Neutral at UBS
01/31/22 HSBC
dLocal upgraded to Buy from Hold at HSBC
DOW Dow Inc.
$64.19 /

+0.895 (+1.41%)

04/01/22 Citi
Citi initiates chemicals pair trade of long Down, short Ecolab
03/18/22 Deutsche Bank
Dow Inc. price target raised to $66 from $65 at Deutsche Bank
02/08/22 Piper Sandler
Dow Inc. price target raised to $76 from $73 at Piper Sandler
01/28/22 BMO Capital
Dow Inc. price target raised to $65 from $57 at BMO Capital
CMBM Cambium Networks
$20.29 /

+0.16 (+0.79%)

03/04/22 Jefferies
Cambium Networks cut to Hold at Jefferies on concern about ramping expectations
03/04/22 Jefferies
Cambium Networks downgraded to Hold from Buy at Jefferies
02/18/22 Raymond James
Cambium Networks price target raised to $43 from $35 at Raymond James
01/28/22 Raymond James
Cambium Networks double upgraded to Strong Buy at Raymond James
RENT Rent The Runway
$5.72 /

+0.37 (+6.92%)

03/29/22 Jefferies
Rent The Runway to benefit from wedding boom, says Jefferies
03/17/22 Jefferies
Jefferies starts Rent The Runway at Buy, says stock offers compelling value
03/17/22 Jefferies
Rent The Runway initiated with a Buy at Jefferies
12/09/21 Morgan Stanley
Rent The Runway path to profitability still underestimated, says Morgan Stanley
PTGX Protagonist Therapeutics
$25.52 /

+1.955 (+8.30%)

02/11/22 BTIG
Protagonist Therapeutics initiated with a Buy at BTIG
02/11/22 BTIG
Protagonist Therapeutics initiated with a Buy at BTIG
11/15/21 JMP Securities
Protagonist Therapeutics price target raised to $70 from $60 at JMP Securities
11/04/21 Piper Sandler
Piper 'pleasantly surprised' by Protagonist Therapeutics' ASH abstracts
OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

03/17/22 Piper Sandler
OncoCyte price target lowered to $1.80 from $3.10 at Piper Sandler
03/14/22 KeyBanc
KeyBanc downgrades OncoCyte to Sector Weight
03/14/22 KeyBanc
OncoCyte downgraded to Sector Weight from Overweight at KeyBanc
03/11/22 Lake Street
OncoCyte price target lowered to $6 from $11 at Lake Street
ES Eversource
$92.52 /

-0.41 (-0.44%)

03/09/22 Wolfe Research
Eversource downgraded to Peer Perform from Outperform at Wolfe Research
02/23/22 BofA
Eversource cut to Underperform at BofA after reduced offshore wind targets
02/23/22 BofA
Eversource downgraded to Underperform from Neutral at BofA
01/10/22 BMO Capital
Eversource downgraded to Market Perform from Outperform at BMO Capital
VLNS Valens
$1.30 /

+0.08 (+6.56%)

RENT Rent The Runway
$5.72 /

+0.37 (+6.92%)

PTGX Protagonist Therapeutics
$25.52 /

+1.955 (+8.30%)

OCX OncoCyte
$1.26 /

-0.02 (-1.56%)

ES Eversource
$92.52 /

-0.41 (-0.44%)

DOW Dow Inc.
$64.19 /

+0.895 (+1.41%)

DLO dLocal
$27.55 /

+0.725 (+2.70%)

CMBM Cambium Networks
$20.29 /

+0.16 (+0.79%)

ANSS Ansys
$295.81 /

+4.49 (+1.54%)

AIRG Airgain
$6.98 /

+0.065 (+0.94%)

AGX Argan
$39.55 /

-0.15 (-0.38%)

  • 27
    Oct
  • 21
    Oct
  • 16
    Jun
  • 03
    Jun
  • 03
    Jun
RENT Rent The Runway
$5.72 /

+0.37 (+6.92%)

VLNS Valens
$1.30 /

+0.08 (+6.56%)

RENT Rent The Runway
$5.72 /

+0.37 (+6.92%)

DOW Dow Inc.
$64.19 /

+0.895 (+1.41%)

DLO dLocal
$27.55 /

+0.725 (+2.70%)

AIRG Airgain
$6.98 /

+0.065 (+0.94%)

RENT Rent The Runway
$5.72 /

+0.37 (+6.92%)

DOW Dow Inc.
$64.19 /

+0.895 (+1.41%)

DLO dLocal
$27.55 /

+0.725 (+2.70%)

CMBM Cambium Networks
$20.29 /

+0.16 (+0.79%)

AGX Argan
$39.55 /

-0.15 (-0.38%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.